Restless legs syndrome/Willis Ekbom disease: Evaluation and treatment

International Review of Psychiatry

Volumn 26, Issue 2, 2014, Pages 248-262

  Allen, Richard P ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; IRON; METHADONE; NALOXONE PLUS OXYCODONE; OXYCODONE; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

AKATHISIA; ANXIETY DISORDER; ARTICLE; CLINICAL EVALUATION; COMORBIDITY; DAYTIME SOMNOLENCE; DEPRESSION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; FAMILY HISTORY; GENETICS; HISTORY; HUMAN; NEUROBIOLOGY; NEUROLEPTIC INDUCED AKATHISIA; PERIODIC LIMB MOVEMENT DISORDER; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRY; RESTLESS LEGS SYNDROME; SYMPTOMATOLOGY; TREATMENT INDICATION; WILLIS EKBOM DISEASE; COMPLICATION; MENTAL DISEASE;

DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGONISTS; HUMANS; MENTAL DISORDERS; RESTLESS LEGS SYNDROME; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84901828051     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2014.904279     Document Type: Article

References (82)

1. Abetz, L., Arbuckle, R., Allen, R. P., Garcia-Borreguero, D., Hening, W., Walters, A. S., Kirsch, J. M. (2006). The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Medicine, 7, 340-349.
2. Akpinar, S. (1982). Treatment of restless legs syndrome with levodopa plus benserazide [letter]. Archives of Neurology, 39, 739.
3. Allen, R. P., Adler, C. H., Du, W., Butcher, A., Bregman, D. B., & Earley, C. J. (2011). Clinical Efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: A multi-centred, placebo-controlled preliminary clinical trial. Sleep Medicine, 12, 906-913. doi: S1389-9457(11)00232-2[pii]10. 1016/j. sleep. 2011. 06. 009
4. Allen, R. P., Barker, P. B., Horska, A., & Earley, C. J. (2013). Thalamic glutamate/glutamine in restless legs syndrome: Increased and related to disturbed sleep. Neurology, 80, 2028-2034. doi: 10. 1212/WNL. 0b013e318294b3f6
5. Allen, R. P., Barker, P. B., Wehrl, F., Song, H. K., & Earley, C. J. (2001). MRI measurement of brain iron in patients with restless legs syndrome. Neurology, 56, 263-265.
6. Allen, R. P., Chen, C., Garcia-Borreguero, D., Polo, O., DuBrava, S., Miceli, J., Winkelman, J. W. (2014). Comparison of pregabalin with pramipexole for restless legs syndrome. New England Journal of Medicine, 370, 621-631. doi: 10. 1056/ NEJMoa1303646
7. Allen, R. P., & Earley, C. J. (1996). Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep, 19, 205-213.
8. Allen, R. P., & Earley, C. J. (2007). The role of iron in restless legs syndrome. Movement Disorders, 22, S440 - S448.
9. Allen, R. P., La Buda, M. C., Becker, P., & Earley, C. J. (2002). Family history study of the restless legs syndrome. Sleep Medicine, 3 (Suppl), S3-7.
10. Allen, R. P., Picchietti, D. L., Garcia-Borreguero, D., Ondo, W. G., Walters, A. S., Winkelman, J. W., Lee, H. B. (in press). Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria-history, rationale, description, and signifi cance. Sleeep Medicine.
11. Allen, R. P., Picchietti, D., Hening, W. A., Trenkwalder, C., Walters, A. S., & Montplaisir, J. (2003). Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Medicine, 4, 101-119.
12. Allen, R. P., Stillman, P., & Myers, A. J. (2010). Physiciandiagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Medicine, 11, 31-37. doi: S1389-9457 (09)00157-9[pii]10. 1016/j. sleep. 2009. 03. 007
13. Allen, R. P., Walters, A. S., Montplaisir, J., Hening, W., Myers, A., Bell, T. J., & Ferini-Strambi, L. (2005). Restless legs syndrome prevalence and impact: REST general population study. Archives of Internal Medicine, 165, 1286-1292.
14. Barton, A., Bowie, J., & Ebmeire, M. (1990). Low plasma iron status and akathisia. Journal of Neurology, Neurosurgery and Psychiatry, 53, 671-674.
15. Bassetti, C. L., Mauerhofer, D., Gugger, M., Mathis, J., & Hess, C. W. (2001). Restless legs syndrome: A clinical study of 55 patients. European Neurology, 45, 67-74.
16. Bayard, M., Bailey, B., Acharya, D., Ambreen, F., Duggal, S., Kaur, T., Tudiver, F. (2011). Bupropion and restless legs syndrome: A randomized controlled trial. Journal of the American Board of Family Medicine, 24, 422-428. doi: 24/4/422[pii]10. 3122/jabfm. 2011. 04. 100173
17. Beard, G. (1880). A Practical Treatise on Nervous Exhaustion. New York: William Wood.
18. Benes, H., Garcia-Borreguero, D., Ferini-Strambi, L., Schollmayer, E., Fichtner, A., & Kohnen, R. (2012). Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Medicine. doi: 10. 1016/j. sleep. 2011. 09. 016
19. Bogan, R. K., Fry, J. M., Schmidt, M. H., Carson, S. W., & Ritchie, S. Y. (2006). Ropinirole in the treatment of patients with restless legs syndrome: A US-based randomized, double-blind, placebo-controlled clinical trial. Mayo clinic Procedings, 81, 17-27.
20. Boghen, D., Lamothe, L., Elie, R., Godbout, R., & Montplaisir, J. (1986). The treatment of the restless legs syndrome with clonazepam: A prospective controlled study. Canadian Journal of Neurological Science, 13, 245-247.
21. Brown, K. W., Glen, S. E., & White, T. (1987). Low serum iron status and akathisia. Lancet, 1, 1234-1236.
22. Catoire, H., Dion, P. A., Xiong, L., Amari, M., Gaudet, R., Girard, S. L., Rouleau, G. A. (2011). Restless legs syndromeassociated MEIS1 risk variant influences iron homeostasis. Annals of Neurology, 70, 170-175. doi: 10. 1002/ana. 22435
23. Chengappa, K. N., Baker, R. W., & Baird, J. (1993). Iron for chronic and persistent akathisia. Journal of Clinical Psychiatry, 54, 320-321.
24. Connor, J. R., Boyer, P. J., Menzies, S. L., Dellinger, B., Allen, R. P., & Earley, C. J. (2003). Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 61, 304-309.
25. Connor, J. R., Wang, X., Allen, R. P., Beard, J., Wiesinger, J. A., Felt, B. T., & Earley, C. J. (2009). Altered dopaminergic profi le in the putamen and substantia nigra in restless leg syndrome. Brain, 132, 2403-2412. doi: awp125[pii]10. 1093/brain/ awp125
26. Corrigan, M. H., Denahan, A. Q., Wright, C. E., Ragual, R. J., & Evans, D. L. (2000). Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety, 11, 58-65.
27. Earley, C. J., & Allen, R. P. (1996). Pergolide and carbidopa/ levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep, 19, 801-810.
28. Earley, C. J., & Allen, R. P. (2006). Restless legs syndrome augmentation associated with tramadol. Sleep Medicine, 7, 592-593.
29. Earley, C. J., Heckler, D., & Allen, R. P. (2001). IV iron treatment for the restless legs syndrome (RLS). Sleep, 24, A359.
30. Earley, C. J., Horska, A., Mohamed, M. A., Barker, P. B., Beard, J. L., & Allen, R. P. (2009). A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine, 10, 206-211.
31. Earley, C. J., Kuwabara, H., Wong, D. F., Gamaldo, C., Salas, R., Brasic, J., Allen, R. P. (2011). The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep, 34, 341-347.
32. Earley, C. J., Kuwabara, H., Wong, D. F., Gamaldo, C., Salas, R. E., Brasic, J. R., Allen, R. P. (2013). Increased synaptic dopamine in the putamen in restless legs syndrome. Sleep, 36, 51-57. doi: 10. 5665/sleep. 2300
33. Ekbom, K. A. (1945). Restless Legs (H. Frey, Trans. ). Stockholm: Ivar Haeggströms.
34. Gamaldo, C., Benbrook, A. R., Allen, R. P., Oguntimein, O., & Earley, C. J. (2009). Evaluating daytime alertness in individuals with restless legs syndrome (RLS) compared to sleep restricted controls. Sleep Medicine, 10, 134-138.
35. Garcia-Borreguero, D. (2004). Augmentation: Understanding a key feature of RLS. Sleep Medicine, 5, 5-6.
36. Garcia-Borreguero, D., Hogl, B., Ferini-Strambi, L., Winkelman, J., Hill-Zabala, C., Asgharian, A., & Allen, R. (2012). Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis- Ekbom disease): Results from a prospective, multicenter study over 66 weeks. Movement Disorders, 27, 277-283. doi: 10. 1002/mds. 24889
37. Garcia-Borreguero, D., Kohnen, R., Silber, M. H., Winkelman, J. W., Earley, C. J., Hogl, B., Allen, R. P. (2013). The long-term treatment of restless legs syndrome/Willis- Ekbom disease: Evidence-based guidelines and clinical consensus best practice guidance: A report from the International Restless Legs Syndrome Study Group. Sleep Medicine, 14, 675-684. doi: 10. 1016/j. sleep. 2013. 05. 016
38. Garcia-Borreguero, D., Larrosa, O., de la Llave, Y., Verger, K., Masramon, X., & Hernandez, G. (2002). Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology, 59, 1573-1579.
39. Garcia-Borreguero, D., Montagna, P., Trenkwalder, C. group, R. R. s. (2003). Ropinirole is Effective in the Treatment of Restless Legs Syndrome (RLS): A Double-Blind Placebo-Controlled 12-Week Study Conducted in 10 Countries. Neurology, 60(suppl 1), A11-12.
40. Giorgi, L., Ritchie, S. Y., & Kirsch, J. M. (2006). Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score - or - 24 points - Data from the ropinirole clinical trial programme. Current Medical Research Opinion, 22, 1867-1877.
41. Grote, L., Leissner, L., Hedner, J., & Ulfberg, J. (2009). A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders, 24, 1445-1452.
42. Hening, W. A., Walters, A. S., Wagner, M., Rosen, R., Chen, V., Kim, S., Thai, O. (1999). Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep, 22, 901-912.
43. Hoque, R., & Chesson, A. L., Jr. (2010). Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: Literature review, qualitative scoring, and comparative analysis. Journal of Clinical Sleep Medicine, 6, 79-83.
44. Inami, Y., Horiguchi, J., Nishimatsu, O., Sasaki, A., Sukegawa, T., Katagiri, H., & Yamawaki, S. (1997). A polysomnographic study on periodic limb movements in patients with restless legs syndrome and neuroleptic-induced akathisia. Hiroshima Journal of Medical Science, 46, 133-141.
45. Inoue, Y., Uchimura, N., Kuroda, K., Hirata, K., & Hattori, N. (2012). Long-term Efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Progress in Neuropsychopharmacology and Biological Psychiatry, 36, 251-257. doi: 10. 1016/j. pnpbp. 2011. 10. 009
46. International Restless Legs Syndrome Study Group. (2003). Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Medicine, 4, 121-132.
47. Kallweit, U., Siccoli, M. M., Poryazova, R., Werth, E., & Bassetti, C. L. (2009). Excessive daytime sleepiness in idiopathic restless legs syndrome: Characteristics and evolution under dopaminergic treatment. European Neurology, 62, 176-179. doi: 000228261 [pii]10. 1159/000228261
48. Lee, D. O., Ziman, R. B., Perkins, A. T., Poceta, J. S., Walters, A. S., Barrett, R. W., & Group, X. P. S. (2011). A randomized, doubleblind, placebo-controlled study to assess the Efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. Journal of Clinical Sleep Medicine, 7, 282-292. doi: 10. 5664/JCSM. 1074
49. Lee, H. B., Hening, W. A., Allen, R. P., Kalaydjian, A. E., Earley, C. J., Eaton, W. W., & Lyketsos, C. G. (2008). Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. Journal of Neuropsychiatry and Clinal Neuroscience, 20, 101-105.
50. Lugaresi, E., Coccagna, G., Berti Ceroni, G., & Ambrosetto, C. (1968). Restless legs syndrome and nocturnal myoclonus. In H. Gastaut, E. Lugaresi & G. Berti Ceroni (Eds), The Abnormalites of Sleep in Man ( pp. 285-294 ). Bologna: Aulo Gaggi Editore.
51. Matthews, W. B. (1979). Treatment of the restless legs syndrome with clonazepam [letter]. British Medical Journal, 1, 751.
52. Montplaisir, J., Boucher, S., Poirier, G., Lavigne, G., Lapierre, O., & Lesperance, P. (1997). Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria. Movement Disorders, 12, 61-65.
53. Montplaisir, J., Lorrain, D., & Godbout, R. (1991). Restless legs syndrome and periodic leg movements in sleep: The primary role of dopaminergic mechanism. European Neurology, 31, 41-43.
54. Nardone, R., Ausserer, H., Bratti, A., Covi, M., Lochner, P., Marth, R., & Tezzon, F. (2006). Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome. Acta Neurologica Scandinavica, 114, 244-249.
55. Oertel, W., Trenkwalder, C., Benes, H., Ferini-Strambi, L., Hogl, B., Poewe, W., Garcia-Borreguero, D. (2011). Longterm safety and Efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: A 5-year open-label extension study. Lancet Neurologyogy, 10, 710-720. doi: 10. 1016/S1474-4422(11)70127-2
56. Ondo, W. G. (2005). Methadone for refractory restless legs syndrome. Movement Disorders, 20, 345-348.
57. Ondo, W. G. (2010). Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Medicine, 11, 494-496. doi: S1389-9457(10)00036-5 [pii] 10. 1016/j. sleep. 2009. 12. 002
58. Oppenheim, H. (1923). Lehrbuch der nervenkrankheiten. Berlin: Karger.
59. Pantaleo, N. P., Hening, W. A., Allen, R. P., & Earley, C. J. (2010). Pregnancy accounts for most of the gender differences in prevalence of familial RLS. Sleep Medicine, 11, 310-313.
60. Picchietti, D., Allen, R. P., Walters, A. S., Davidson, J. E., Myers, A., & Ferini-Strambi, L. (2007). Restless legs syndrome: Prevalence and impact in children and adolescents - The Peds REST study. Pediatrics, 120, 253-266.
61. Rizzo, G., Manners, D., Testa, C., Tonon, C., Vetrugno, R., Marconi, S., Lodi, R. (2013). Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging. Movement Disorders. doi: 10. 1002/mds. 25576
62. Scalise, A., Cadore, I. P., & Gigli, G. L. (2004). Motor cortex excitability in restless legs syndrome. Sleep Medicine, 5, 393-396.
63. Scalise, A., Pittaro-Cadore, I., Janes, F., Marinig, R., & Gigli, G. L. (2010). Changes of cortical excitability after dopaminergic treatment in restless legs syndrome. Sleep Medicine, 11, 75-81. doi: S1389-9457(09)00222-6 [pii] 10. 1016/j. sleep. 2009. 05. 003
64. Schmidauer, C., Sojer, M., Seppi, K., Stockner, H., Hogl, B., Biedermann, B., Poewe, W. (2005). Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Annals of Neurology, 58, 630-634.
65. Selak, I. (2001). Pregabalin (Pfi zer). Current Opinion in Investigational Drugs, 2, 828-834.
66. Silver, N., Allen, R. P., Senerth, J., & Earley, C. J. (2011). A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Medicine, 12, 440-444. doi: S1389-9457(10)00371-0 [pii] 10. 1016/j. sleep. 2010. 11. 002
67. Stefansson, H., Rye, D. B., Hicks, A., Petursson, H., Ingason, A., Thorgeirsson, T. E., Stefansson, K. (2007). A genetic risk factor for periodic limb movements in sleep. New England Journal of Medicine, 357, 639-647.
68. Stiasny-Kolster, K., Kohnen, R., Moller, J. C., Trenkwalder, C., & Oertel, W. H. (2006). Validation of the ' L-DOPA test ' for diagnosis of restless legs syndrome. Movement Disorders, 21, 1333-1339.
69. Tergau, F., Wischer, S., & Paulus, W. (1999). Motor system excitability in patients with restless legs syndrome. Neurology, 52, 1060-1063.
70. Trenkwalder, C., Benes, H., Grote, L., Garcia-Borreguero, D., Hogl, B., Hopp, M., Group, R. S. (2013). Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: A doubleblind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurology, 12, 1141-1150. doi: 10. 1016/ S1474-4422(13)70239-4
71. Vetrugno, R., La Morgia, C., D ' Angelo, R., Loi, D., Provini, F., Plazzi, G., & Montagna, P. (2007). Augmentation of restless legs syndrome with long-term tramadol treatment. Movement Disorders, 22, 424-427.
72. Walters, A. S., Aldrich, M. A., Allen, R. P., Ancoli-Israel, S., Buchholz, D., Chockroverty, S., Zucconi, M. (1995). Toward a better defi nition of the restless legs syndrome. Movement Disorders, 10, 634-642.
73. Walters, A. S., Ondo, W. G., Kushida, C. A., Becker, P. M., Ellenbogen, A. L., Canafax, D. M., & Barrett, R. W. (2009). Gabapentin enacarbil in restless legs syndrome: A phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clinical Neuropharmacol ogy, 32, 311-320.
74. Walters, A. S., Wagner, M. L., Hening, W. A., Grasing, K., Mills, R., Chokroverty, S., & Kavey, N. (1993). Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep, 16, 327-332.
75. Wang, J., O'Reilly, B., Venkataraman, R., Mysliwiec, V., & Mysliwiec, A. (2009). Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Medicine.
76. Willis, T. (1683). Two Discourses Concerning the Soul of Brutes. London: Dring, Harper, & Leigh.
77. Willis, T. (1685). The London Practice of Physick. London: Bassett & Crooke.
78. Winkelmann, J., Czamara, D., Schormair, B., Knauf, F., Schulte, E. C., Trenkwalder, C., Meitinger, T. (2011). Genome-wide association study identifi es novel restless legs syndrome susceptibility loci on 2p14 and 16q12. 1. PLoS Genetics, 7, e1002171. doi: 10. 1371/journal. pgen. 1002171
79. Winkelmann, J., Prager, M., Lieb, R., Pfi ster, H., Spiegel, B., Wittchen, H. U., Strohle, A. (2005). ' Anxietas tibiarum '. Depression and anxiety disorders in patients with restless legs syndrome. Journal of Neurology, 252, 67-71.
80. Winkelman, J. W., Sethi, K. D., Kushida, C. A., Becker, P. M., Koester, J., Cappola, J. J., & Reess, J. (2006). Efficacy and safety of pramipexole in restless legs syndrome. Neurology, 67, 1034-1039.
81. Winkelmann, J., Schormair, B., Lichtner, P., Ripke, S., Xiong, L., Jalilzadeh, S., Meitinger, T. (2007). Genome-wide association study of restless legs syndrome identifi es common variants in three genomic regions. Nature Genetics, 39, 1000-1006.
82. Wittmaack, T. (1861). Pathologie und Therapie der Sensibilitatneurosen. Leipzig: Schafer.